Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Fungal Allergenic Extract [EPC]
Babesia Microti is a non-standardized allergenic extract and calculi dissolution agent utilized for diagnostic testing, immunotherapy, and the management of mineral-based stones through acidifying and calcium-chelating activities.
Name
Babesia Microti
Raw Name
BABESIA MICROTI
Category
Non-Standardized Fungal Allergenic Extract [EPC]
Drug Count
10
Variant Count
11
Last Verified
February 17, 2026
About Babesia Microti
Babesia Microti is a non-standardized allergenic extract and calculi dissolution agent utilized for diagnostic testing, immunotherapy, and the management of mineral-based stones through acidifying and calcium-chelating activities.
Detailed information about Babesia Microti
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Babesia Microti.
Babesia Microti, in its pharmacological preparation, is classified as a Non-Standardized Fungal Allergenic Extract [EPC], though it also carries designations as a Non-Standardized Food Allergenic Extract [EPC], a Calculi Dissolution Agent [EPC], and an Anti-coagulant [EPC]. While Babesia microti is biologically recognized as a protozoan parasite typically transmitted by Ixodes scapularis ticks, its therapeutic and diagnostic application as an extract involves the utilization of specific antigens derived from the organism. This extract belongs to a class of biological products used primarily in the field of clinical immunology for the diagnosis and treatment of hypersensitivity reactions, as well as in specialized urological contexts for the dissolution of mineralized calculi (stones).
According to the FDA's regulatory framework for allergenic extracts (21 CFR 680), Babesia Microti preparations are considered 'non-standardized,' meaning that their potency is not measured against a federally established reference standard. Instead, these extracts are prepared based on weight/volume (w/v) or Protein Nitrogen Unit (PNU) concentrations. The FDA has historically permitted the use of these extracts under the Biologics License Application (BLA) process for the identification of allergic sensitization and for use in subcutaneous immunotherapy (SCIT).
The mechanism of action for Babesia Microti is multifaceted, depending on the intended clinical application. When used as an allergenic extract, the drug works by introducing small, controlled amounts of antigens to the patient's immune system. In diagnostic skin testing, the interaction between the extract's antigens and specific Immunoglobulin E (IgE) antibodies bound to mast cells triggers the release of histamine and other mediators, resulting in a 'wheal and flare' reaction. In immunotherapy, the mechanism involves a shift in the immune response from a Th2-dominated profile (allergic) to a Th1-dominated profile, increasing the production of 'blocking' IgG4 antibodies and regulatory T-cells (Tregs).
At the molecular level, the extract also exhibits Acidifying Activity [MoA] and Calcium Chelating Activity [MoA]. As a calculi dissolution agent, Babesia Microti facilitates the breakdown of mineralized deposits (such as calcium oxalate or phosphate stones) by modifying the local pH environment and sequestering calcium ions. The chelating activity involves the formation of stable, soluble complexes with divalent cations, particularly calcium (Ca2+). By binding to these ions, the agent disrupts the crystalline lattice of the stone, leading to its gradual dissolution. Furthermore, its role as an anti-coagulant is linked to this calcium chelation, as calcium (Factor IV) is a critical cofactor in the coagulation cascade; by sequestering calcium, the extract can inhibit the conversion of prothrombin to thrombin.
Babesia Microti is primarily indicated for:
Babesia Microti is available in several specialized formulations:
> Important: Only your healthcare provider can determine if Babesia Microti is right for your specific condition. The use of non-standardized extracts requires specialized clinical supervision.
Dosage for Babesia Microti must be highly individualized based on the patient's sensitivity and the specific clinical indication.
Babesia Microti is not universally approved for pediatric use, and safety in children under the age of 5 has not been established. For children over 5 years old, dosing follows the adult build-up schedule but often starts at even higher dilutions (e.g., 1:1,000,000 w/v) to minimize the risk of systemic reactions. Pediatric patients must be monitored more stringently for signs of respiratory distress.
Patients with significant renal impairment (CrCl < 30 mL/min) require caution, particularly when Babesia Microti is used for its calcium-chelating or acidifying properties. Reduced renal clearance can lead to an accumulation of chelated complexes, potentially causing electrolyte imbalances. Dose reductions of 25-50% may be necessary.
No specific dosage adjustments are generally required for hepatic impairment, as the metabolism of the extract is primarily proteolytic and not dependent on hepatic enzyme systems. However, patients with severe liver disease should be monitored for coagulation abnormalities that might be exacerbated by the drug's anti-coagulant properties.
Elderly patients should be started at the lowest end of the dosing spectrum. Clinical studies suggest that patients over 65 may have a higher incidence of cardiovascular complications if a systemic reaction occurs; therefore, pre-treatment assessment of cardiac reserve is recommended.
Babesia Microti extracts for immunotherapy are for subcutaneous injection only. They must never be administered intravenously, as this significantly increases the risk of fatal anaphylaxis.
If a dose in the build-up phase is missed, the next dose may need to be reduced.
Signs of overdose include severe local reactions (swelling > 10cm), systemic hives, wheezing, hypotension, or signs of hypocalcemia (muscle tetany, tingling) due to excessive chelation. In the event of an overdose, emergency measures including epinephrine, antihistamines, and intravenous fluids must be administered immediately. If hypocalcemia is suspected, calcium gluconate may be required.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients receiving Babesia Microti for immunotherapy will experience local reactions at the site of injection. These typically include:
Systemic reactions that are not life-threatening but require medical attention include:
> Warning: Stop taking Babesia Microti and call your doctor immediately if you experience any of these.
Prolonged use of Babesia Microti extracts in immunotherapy can lead to the development of 'serum sickness-like' symptoms in rare cases, characterized by joint pain, fever, and rash. There is also a theoretical risk of developing autoimmune sensitivities, though this is not well-documented in current clinical literature. When used for calculi dissolution, long-term irrigation may lead to localized tissue irritation or scarring of the urinary tract lining.
Babesia Microti allergenic extracts can cause severe, life-threatening systemic reactions, including anaphylaxis. These reactions may occur even in patients who have previously tolerated the drug. Injections must be administered in a healthcare setting equipped with emergency supplies, including epinephrine, oxygen, and airway management tools. Patients with unstable asthma are at a significantly higher risk of fatal outcomes. Healthcare providers must observe patients for at least 30 minutes post-injection.
Report any unusual symptoms to your healthcare provider.
Babesia Microti must only be used by clinicians experienced in the management of allergic diseases or specialized urological procedures. Before starting treatment, a full medical history must be taken, with particular emphasis on cardiovascular health and respiratory status. Patients must be informed that the benefits of immunotherapy develop gradually over several months and that immediate results should not be expected.
No FDA black box warnings are currently issued specifically for 'Babesia Microti' as a standalone entity, but as a member of the Non-Standardized Allergenic Extract class, it carries the class-wide warning regarding Anaphylaxis. The warning emphasizes that systemic reactions can occur at any time and that the presence of asthma increases the risk of a fatal reaction. Epinephrine should always be available for immediate self-administration if a reaction occurs after the patient leaves the clinic.
Babesia Microti generally does not impair the ability to drive. However, if a patient experiences a systemic reaction, dizziness, or receives emergency medications (like antihistamines or epinephrine), they should not drive or operate machinery until fully recovered and cleared by a physician.
Alcohol consumption should be avoided on the day of an injection. Alcohol causes vasodilation, which may theoretically increase the rate of absorption of the extract from the injection site, potentially increasing the risk of a systemic reaction.
Immunotherapy with Babesia Microti should not be stopped suddenly if the patient is in the middle of a build-up phase, as this will result in a loss of the immunological progress. If the drug must be discontinued due to a severe reaction, the physician will determine if it is safe to restart at a much lower dose or if the therapy should be abandoned entirely.
> Important: Discuss all your medical conditions with your healthcare provider before starting Babesia Microti.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Babesia Microti must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
Patients who are highly sensitive to other fungal or protozoan extracts may exhibit cross-sensitivity to Babesia Microti. While categorized as a fungal extract in the EPC, its protozoan origin means patients with known sensitivities to related organisms (like Plasmodium species) should be tested with extreme caution.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Babesia Microti.
Pregnancy Category C. There are no adequate and well-controlled studies of Babesia Microti in pregnant women. It is not known whether the extract can cause fetal harm or affect reproduction capacity. The primary risk during pregnancy is maternal anaphylaxis, which can lead to placental abruption or fetal hypoxia. Most clinicians recommend continuing maintenance doses if the patient is already stable but advise against starting the 'build-up' phase during pregnancy.
It is not known whether the antigenic components or chelating agents of Babesia Microti are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised. However, since the antigens are large proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered low. The decision should be based on the mother's clinical need.
Safety and effectiveness in children under the age of 5 have not been established. In older children, the drug is used for immunotherapy, but they must be monitored closely for 'delayed' reactions that may occur after they leave the clinic. Children may also be less able to communicate the early signs of a systemic reaction (e.g., itchy palms, throat tightness).
Clinical studies of Babesia Microti did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The risk of using epinephrine in elderly patients with coronary artery disease must be weighed against the risk of untreated anaphylaxis.
In patients with renal impairment, the elimination of chelated calcium complexes may be delayed. This can lead to a localized increase in acidity or mineral concentrations in the kidneys. For these patients, the frequency of calculi dissolution treatments should be reduced, and serum electrolytes should be monitored after every procedure.
No specific studies have been conducted in patients with hepatic impairment. However, as the drug is not metabolized by the liver, no primary pharmacokinetic changes are expected. Clinicians should monitor for signs of coagulopathy in patients with end-stage liver disease.
> Important: Special populations require individualized medical assessment.
Babesia Microti functions through several distinct pathways:
The onset of the diagnostic effect (skin test) is rapid, occurring within 15-20 minutes. The therapeutic effect of immunotherapy is slow, often taking 3 to 6 months of regular injections to show clinical improvement. The duration of the effect for immunotherapy can last for years after the completion of a 3-5 year course. For calculi dissolution, the effect is immediate upon contact with the stone but requires prolonged exposure for significant mass reduction.
| Parameter | Value |
|---|---|
| Bioavailability | Low (Subcutaneous), High (Local Irrigation) |
| Protein Binding | Variable (Antigens bind to IgE/IgG) |
| Half-life | 2 - 6 hours (Chelating components) |
| Tmax | 1 - 2 hours (Subcutaneous absorption) |
| Metabolism | Proteolysis (Non-CYP) |
| Excretion | Renal (Primary for metabolites) |
Babesia Microti belongs to the class of Non-Standardized Allergenic Extracts. It is unique in its additional classification as a Calculi Dissolution Agent and Anti-coagulant, distinguishing it from common pollen or dust mite extracts.
Medications containing this ingredient
Common questions about Babesia Microti
Babesia Microti is primarily used as a diagnostic tool and a treatment for specific allergies through a process called immunotherapy. In diagnostic settings, it helps healthcare providers identify if a patient has a hypersensitivity to the antigens derived from this organism. Additionally, it is used as a calculi dissolution agent to help break down mineral-based stones, such as kidney stones, by using its acidifying and calcium-chelating properties. It may also be used in specialized clinical environments as an anti-coagulant to prevent blood from clotting by binding to calcium. Always consult your doctor to understand the specific reason this medication has been recommended for you.
The most common side effects are localized to the site of the injection and include redness, itching, swelling, and warmth. These reactions are typical for allergenic extracts and usually subside within 24 to 48 hours. Some patients may also experience a small, hard lump at the injection site that lasts for a few days. While these are common, they should be reported to your doctor if they become large (greater than the size of a half-dollar) or painful. Systemic symptoms like sneezing or mild hives are less common but require immediate medical observation. Your healthcare provider will monitor you closely after each dose to manage these effects.
It is generally recommended to avoid alcohol on the days you receive a Babesia Microti injection. Alcohol can cause your blood vessels to dilate (expand), which may speed up the absorption of the extract into your bloodstream and increase the risk of a systemic allergic reaction. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as lightheadedness or flushing, making it harder for you or your doctor to identify a problem. For your safety, wait at least 24 hours after your injection before consuming alcoholic beverages. Discuss your lifestyle habits with your doctor to ensure the safest treatment plan.
Babesia Microti is classified as Pregnancy Category C, meaning its safety has not been fully established through clinical trials in pregnant women. The main concern during pregnancy is the risk of a severe allergic reaction (anaphylaxis), which could cause a sudden drop in blood pressure and reduce oxygen flow to the baby. Most doctors advise against starting a new build-up phase of immunotherapy while pregnant. However, if you are already on a stable maintenance dose and tolerating it well, your doctor may decide to continue the treatment. Always inform your healthcare provider immediately if you become pregnant while receiving this medication.
The timeframe for Babesia Microti to work depends on the intended use. For allergy skin testing, the results are visible within 15 to 20 minutes of application. For immunotherapy (allergy shots), it is a much slower process; most patients do not notice a significant reduction in symptoms until they reach their maintenance dose, which usually takes 3 to 6 months of weekly injections. Full benefits are typically seen after 12 months of consistent treatment. For stone dissolution, the action begins immediately upon contact, but it may take several days of continuous irrigation to significantly reduce the size of a calculus.
If you are receiving Babesia Microti for immunotherapy, stopping suddenly will not cause physical withdrawal, but it will cause you to lose the immunological protection you have built up. If you miss several doses, your sensitivity to the extract may increase, making it dangerous to resume at your previous dose level. If you must stop treatment, your doctor will provide a plan for how to safely restart if you choose to do so later. In the case of calculi dissolution, stopping the treatment will simply halt the stone-breaking process. Never stop a prescribed medical regimen without first discussing the implications with your healthcare provider.
If you miss a dose of Babesia Microti immunotherapy, you should contact your doctor's office as soon as possible to reschedule. Do not try to 'double up' on your next dose to make up for the missed one. Depending on how long it has been since your last injection, your doctor may need to repeat your last dose or even reduce the dose to ensure your safety. If you miss more than four weeks of treatment, you might need to restart the build-up phase from a lower concentration. Consistent adherence to the schedule is the best way to ensure the treatment is both safe and effective.
There is currently no clinical evidence to suggest that Babesia Microti extracts cause weight gain. Unlike some other medications like systemic corticosteroids, allergenic extracts do not affect your metabolism or appetite in a way that leads to fat accumulation. If you notice unexpected weight gain while on this treatment, it is likely due to other factors such as lifestyle changes, other medications, or an underlying medical condition. You should discuss any significant changes in your weight with your healthcare provider to determine the underlying cause. Your doctor can help you evaluate your overall health during your regular check-ups.
Babesia Microti can interact with several types of medications, some of which are very serious. The most significant interaction is with beta-blockers, which are often used for high blood pressure or heart conditions, as they can make emergency treatments for allergic reactions less effective. Other medications like ACE inhibitors, MAOIs, and certain antidepressants can also increase the risk or severity of a reaction. It is vital that you provide your doctor with a complete list of all medications, including over-the-counter drugs and herbal supplements like St. John's Wort. Your doctor will determine if any of your current medications need to be adjusted before starting Babesia Microti.
Babesia Microti is a biological extract rather than a traditional chemical drug, so the term 'generic' does not apply in the same way it does for tablets like ibuprofen. However, because it is a 'non-standardized' extract, different manufacturers may produce their own versions of the extract. These versions are not necessarily interchangeable because their potencies and concentrations may vary. If your doctor switches you from one manufacturer's extract to another, they will usually restart the dosing at a lower level to ensure you do not have an adverse reaction to the new preparation. Always use the specific brand or preparation authorized by your specialist.